This letter provides insightful perspectives on multiple sclerosis (MS) biomarkers, building upon Behrouz Shademan et al.'s study on miRNA-21, miRNA-155, and miRNA-182 [1]. Beyond these miRNAs, we delve into recent advancements, highlighting promising biomarkers such as ELTD1, CHI3L1, and Fecal Lcn-2. ELTD1 exhibits potential for MS diagnosis, CHI3L1 correlates with disability aspects, and Fecal Lcn-2 serves as a sensitive indicator for gut dysbiosis. Our exploration underscores the evolving landscape of MS biomarker research, urging further investigation for integrating these new markers into diagnostic and monitoring strategies.
Keywords: Biomarkers; Cerebrospinal fluid; Diagnosis; Inflammatory factors; Multiple sclerosis.
Copyright © 2023 Elsevier B.V. All rights reserved.